Italian researchers have potentially found a new biomarker for mesothelioma. The biomarker is a microRNA signature. This would allow doctors to determine if someone’s cancer is mesothelioma or another type of cancer quickly. Mesothelioma is a notoriously hard to treat cancer and early diagnosis is one of the keys to[…]
Mesothelioma
Report Shows that Asbestos Ban Would Benefit Countries Around the World
Banning asbestos could soon be a reality after a study linked asbestos, a toxic naturally occurring mineral, to mesothelioma, lung cancer, and other cancers. The report linked asbestos with different asbestos related diseases in 70 countries. The report was published in May by Environmental Health Perspectives, which is supported by[…]
A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer
Primary Outcome Measures Phase 1 – Establish the recommended Phase 2 dose (RP2D) according to dose-limiting toxicity (DLT) of defined adverse events. [ Time Frame: DLTs within 28 days post-treatment ] Phase 1 -The number and percent of patients in the DLT evaluable set who experienced DLTs from the first administration of study drug[…]
An Inhalable Gene Therapy is Being Tested for Mesothelioma
An inhalable gene therapy could potentially be approved for use in mesothelioma patients. Researchers in Japan have created two different tumor suppressing drugs that work by targeting genetic mutations. The drugs were created for non-small cell cancer and pleural mesothelioma. They are both doing well in the laboratory. The drugs[…]
Niraparib Efficacy in Patient With Unresectable Mesothelioma (NERO)
Primary Outcome Measures Progression-free survival [ Time Frame: From date of randomisation until the date of the first documented progression or date of death from any cause, whichever came first, assessed up to 18 months ] Progression-free survival is the determined by modified RECIST (pleural disease), RECIST 1.1 (for non-pleural disease), investigator reported progression[…]
Drug Repurposing for Mesothelioma
Research at Temple University is looking at four different drug compounds, all used for noncancerous conditions, for treating mesothelioma. The research is part of a drug repurposing project, which tests drugs not typically used for illnesses like cancer to see if they work on the disease. Drug repurposing has become[…]
Immunology and Cytology to Diagnose Mesothelioma
Researchers may have found a better, less invasive way to test for mesothelioma. Normally, a biopsy is done, which requires removing tissue to diagnose mesothelioma, but a new two-part exam might make this procedure a thing of the past. The new test utilizes cytology, which looks at cells in body[…]
Immunological Variables Associated to ICI Toxicity in Cancer Patients
Primary Outcome Measures Modification(s) in the immune blood markers of treated subjects on treatment. [ Time Frame: Assessment: between week 4 and 6 after the first dose of the treatment ] Modification(s) in the immune blood markers including cytokines, immune cells and serum autoantibody level of treated subjects. Modification(s) in the immune blood markers[…]
SMARTEST Trial Hopes to Improve Survival Times for Mesothelioma
Researchers are performing a clinical trial hoping that they can make pleural mesothelioma a more manageable, and even survivable, disease. The clinical trial is being done at Princess Margaret Cancer Center in Toronto. The trial is known as SMARTEST, which stands for Surgery for Mesothelioma After Radiation Therapy using Exquisite[…]
OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition
Primary Outcome Measures Determination of ORR for the combination of OT-101 and pembrolizumab in subjects [ Time Frame: approximately 24 months ] modified RECIST (mRECIST; v1.1) Secondary Outcome Measures PFS, DOR and 6-month and 12-month Overall Survival (OS) will be estimated in all subjects in the ITT population. [ Time Frame: approximately 18 months ] Progression-free Survival (PFS),[…]
Skip to content